Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 159

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial

Open access
Camm, A. J., Toft, E., Torp-Pedersen, C., Vijayaraman, P., Juul-Moller, S., Ip, J., Beatch, G. N., Dickinson, G., Wyse, D. G., for the Scene 2 Investigators·2012·Europace

Abstract

AIMS: Vernakalant is a novel, relatively atrial-selective antiarrhythmic agent for conversion of atrial fibrillation (AF) to sinus rhythm. This study examined the safety and efficacy of vernakalant in converting atrial flutter (AFL) to sinus rhythm. METHODS AND RESULTS: This was a phase 2/3, randomized, double-blind, placebo-controlled trial. Adults with AFL received either a 10 min infusion of 3.0 mg/kg vernakalant (n = 39) or placebo (n = 15). If AFL or AF persisted at the end of a 15 min observation period, a second 10 min infusion of 2.0 mg/kg vernakalant or placebo was administered. The primary efficacy outcome was the proportion of patients who had treatment-induced conversion of AFL to sinus rhythm for a minimum duration of 1 min within 90 min after the start of the first infusion. No patient in the placebo group met the primary outcome. Only one patient receiving vernakalant (1 of 39, 3%) converted to sinus rhythm. A reduced mean absolute ventricular response rate occurred within 50 min in patients receiving vernakalant (mean change from baseline -8.2 b.p.m.) vs. patients receiving placebo (-0.2 b.p.m.) (P = 0.037). A post-hoc analysis revealed that vernakalant increased AFL cycle length by an average of 55 ms, whereas the AFL cycle length was unchanged in the placebo group (P < 0.001). There was no occurrence of 1 : 1 atrio-ventricular conduction. Dysgeusia and sneezing were the most common treatment-related adverse events, consistent with previous reports. CONCLUSION: Vernakalant did not restore sinus rhythm in patients with AFL. Vernakalant modestly slowed AFL and ventricular response rates, and was well tolerated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/europace/eur416

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 22

  1. 2010, Clinical Medicine & Research, 8, 1, 10.3121/cmr.2009.851 · DOI
  2. Waldo, 2008, Journal of the American College of Cardiology, 51, 779, 10.1016/j.jacc.2007.08.066 · DOI · Paper page
  3. Ng, 2008, Mayo Clinic Proceedings, 83, 646, 10.4065/83.6.646 · doi:10.4065/83.6.646
  4. 2008, Circulation, 117, 1101, 10.1161/CIRCULATIONAHA.107.187192 · DOI
  5. Dobrev, 2010, Lancet, 375, 1212, 10.1016/S0140-6736(10)60096-7 · DOI · Paper page
  6. CHIMIENTI, 1995, European Heart Journal, 16, 1943, 10.1093/oxfordjournals.eurheartj.a060852 · DOI
  7. Fedida, 2005, Journal of cardiovascular electrophysiology, 16, 1227, 10.1111/j.1540-8167.2005.50028.x · DOI · Paper page
  8. Dorian, 2007, Journal of cardiovascular pharmacology, 50, 35, 10.1097/FJC.0b013e3180547553 · DOI
  9. 2008, Circulation, 117, 1518, 10.1161/CIRCULATIONAHA.107.723866 · DOI · Paper page
  10. Roy, 2004, Journal of the American College of Cardiology, 44, 2355, 10.1016/j.jacc.2004.09.021 · DOI
  11. Pratt, 2010, The American journal of cardiology, 106, 1277, 10.1016/j.amjcard.2010.06.054 · doi:10.1016/j.amjcard.2010.06.054
  12. 2009, Circulation: Arrhythmia and Electrophysiology, 2, 652, 10.1161/CIRCEP.109.870204 · DOI · Paper page
  13. 1920, Heart, 7, 353
  14. 1920, Acta medica Scandinavica, 53, 469, 10.1111/j.0954-6820.1920.tb18266.x · DOI · Paper page
  15. Glatter, 2001, Circulation, 103, 253, 10.1161/01.CIR.103.2.253 · DOI
  16. VanderLugt, 1999, Circulation, 100, 369, 10.1161/01.CIR.100.4.369 · DOI · Paper page
  17. Volgman, 1998, Journal of the American College of Cardiology, 31, 1414, 10.1016/S0735-1097(98)00078-3 · DOI · Paper page
  18. Writing Committee Members, 2006, Europace, 8, 651, 10.1093/europace/eul097 · DOI · Paper page
  19. Hellestrand, 1982, Heart, 48, 140, 10.1136/hrt.48.2.140 · DOI
  20. 2011, Europace, 13, 161, 10.1093/europace/euq382 · DOI · Paper page
  21. Falk, 1992, Annals of Internal Medicine, 117, 141, 10.1059/0003-4819-117-2-141 · doi:10.1059/0003-4819-117-2-141
  22. Kawabata, 2001, Journal of electrocardiology, 34, 65, 10.1054/jelc.2001.22034 · DOI

Cited by

See all 159

Metadata

Authors
Camm, A. J., Toft, E., Torp-Pedersen, C., Vijayaraman, P., Juul-Moller, S., Ip, J., Beatch, G. N., Dickinson, G., Wyse, D. G., & for the Scene 2 Investigators
Venue
Europace
Published
2012-01-29
Volume
14
Issue
6
Pages
804-809
ISSN
  • 1099-5129 (ISSN-L)
  • 1532-2092
OpenAlex
W2112991023
Cited by
159
References
4
FWCI
20.14
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1093/europace/eur416
The paper
Camm, A. J., Toft, E., Torp-Pedersen, C., Vijayaraman, P., Juul-Moller, S., Ip, J., Beatch, G. N., Dickinson, G., Wyse, D. G., & for the Scene 2 Investigators. (2012). Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial. Europace. https://doi.org/10.1093/europace/eur416

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.